Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Terence W Friedlander

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Journal of the American Geriatrics Society|October 6, 2021
Changes in older adults' life space during lung cancer treatment: A mixed methods cohort studyMelisa L Wong, Ying Shi, Alexander K Smith, et al.
Journal for Immunotherapy of Cancer|May 13, 2021
<i>TERT</i> promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitorIvan de Kouchkovsky, Li Zhang, Errol J Philip, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2024
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With PembrolizumabMatthew I Milowsky, Peter H O'Donnell, Christopher J Hoimes, et al.
The Journal of Urology|June 20, 2019
Identification and Characterization of Circulating Tumor Cells in Men Who have Undergone Prostatectomy for Clinically Localized, High Risk Prostate CancerTerence W Friedlander, Christopher Welty, Archana Anantharaman, et al.
The Oncologist|June 22, 2024
HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gainsXiaolin Zhu, Emily Chan, Michelle L Turski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2025
Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate CancerMatthew D Galsky, Karen A Autio, Christopher R Cabanski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2023
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial CancerPeter H O'Donnell, Matthew I Milowsky, Daniel P Petrylak, et al.
Nature Communications|September 10, 2025
Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancerKevin Chang, Henry M Delavan, Elizabeth Yip, et al.
Cancer|December 9, 2021
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) studyVadim S Koshkin, Nicholas Henderson, Marihella James, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Journal of the American Geriatrics Society|October 6, 2021
Changes in older adults' life space during lung cancer treatment: A mixed methods cohort studyMelisa L Wong, Ying Shi, Alexander K Smith, et al.
Journal for Immunotherapy of Cancer|May 13, 2021
<i>TERT</i> promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitorIvan de Kouchkovsky, Li Zhang, Errol J Philip, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2024
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With PembrolizumabMatthew I Milowsky, Peter H O'Donnell, Christopher J Hoimes, et al.
The Journal of Urology|June 20, 2019
Identification and Characterization of Circulating Tumor Cells in Men Who have Undergone Prostatectomy for Clinically Localized, High Risk Prostate CancerTerence W Friedlander, Christopher Welty, Archana Anantharaman, et al.
The Oncologist|June 22, 2024
HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gainsXiaolin Zhu, Emily Chan, Michelle L Turski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2025
Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate CancerMatthew D Galsky, Karen A Autio, Christopher R Cabanski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2023
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial CancerPeter H O'Donnell, Matthew I Milowsky, Daniel P Petrylak, et al.
Nature Communications|September 10, 2025
Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancerKevin Chang, Henry M Delavan, Elizabeth Yip, et al.
Cancer|December 9, 2021
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) studyVadim S Koshkin, Nicholas Henderson, Marihella James, et al.
Pageof 5